Profound Medical Corp.

Toronto Stock Exchange PRN.TO

Profound Medical Corp. EBIT Margin for the year ending December 31, 2023: -387.93%

Profound Medical Corp. EBIT Margin is -387.93% for the year ending December 31, 2023, a 29.42% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Profound Medical Corp. EBIT Margin for the year ending December 31, 2022 was -549.66%, a -21.85% change year over year.
Profound Medical Corp. EBIT Margin for the year ending December 31, 2021 was -451.10%, a -52.83% change year over year.
Profound Medical Corp. EBIT Margin for the year ending December 31, 2020 was -295.17%, a 18.03% change year over year.
Profound Medical Corp. EBIT Margin for the year ending December 31, 2019 was -360.08%, a 53.90% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Toronto Stock Exchange: PRN.TO

Profound Medical Corp.

CEO	Dr. Arun Swarup Menawat MBA, Ph.D.
IPO Date	July 10, 2018
Location	Canada
Headquarters	2400 Skymark Avenue
Employees	131
Sector	Health Care
Industries Medical Instruments Pharmaceuticals Telehealth

Description

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Key trends

Past 5 years